EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Aptamer-based nanoparticle drug delivery system designed for targeting GPC3-positive liver cancer

Hongxin Zhou, Shuangshuang Dong, Zhan Si, Hao Niu, Jianwen Mao, Yiran Chen, Yuhuan Li, Weizhong Wu

Journal of Pharmaceutical Analysis · 2026-08 · 16 (8) · 101614

DOI: 10.1016/j.jpha.2026.101614 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Pharmaceutical Analysis, 2026-08. Verfasst von Hongxin Zhou und 7 weiteren Autor:innen. Beteiligte Einrichtung: Liver Cancer Institute, Zhongshan Hospital, Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Fudan University, Shanghai, …. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China, Science and Technology Commission of Shanghai Municipality.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Nucleic acid aptamers, short single-stranded DNA (ssDNA) or RNA molecules generated via systematic evolution of ligands by exponential enrichment (SELEX), have emerged as promising alternatives to traditional antibodies owing to their exceptional specificity and affinity. These unique properties render them invaluable tools in both scientific research and clinical theranostics. In recent years, aptamer-functionalized nanomaterials have demonstrated substantial potential as tumor-targeted drug delivery systems, offering notable advantages such as reduced systemic toxicity and enhanced therapeutic efficacy. In this study, we developed a novel targeted drug delivery system specifically designed for glypican-3 (GPC3)-positive hepatocellular carcinoma (HCC) by conjugating the GPC3-targeted aptamer AP613-1 to liposomes encapsulating doxorubicin (DOX). To enhance the biostability and binding affinity of the aptamer, we constructed an aptamer-embedded triangular nanostructure (mTriangle-AP613-1) using a DNA origami technique. Characterization results revealed that the mTriangle-AP613-1 nanostructure exhibited a significantly improved dissociation constant (K D) of 15.2 ± 0.21 nM and enhanced biosafety profiles compared to free aptamers. Both in vitro and in vivo evaluations demonstrated that DOX-loaded mTriangle-AP613-1-liposomes achieved superior tumor growth inhibition in GPC3-positive tumor models compared to control groups. These findings highlight the potential of mTriangle-AP613-1-liposomes (DOX) as a highly effective nanomedicine platform for targeted cancer therapy. Notably, our results underscore the translational value of aptamer-functionalized nanostructures in advancing precision oncology through optimized drug delivery systems.

Schlagwörter

Stichwörter der Autor:innen

DNA origamiDoxorubicinDrug delivery systemGlypican-3Nucleic acid aptamers

Autor:innen und Institutionen

  • Liver Cancer Institute, Zhongshan Hospital, Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Fudan University, Shanghai, 200032, China.
  • Department of Nuclear Medicine, Zhongshan Hospital, Fudan University, Shanghai, 200032, China.

Förderung

  • National Natural Science Foundation of China
  • Science and Technology Commission of Shanghai Municipality

Zitieren

APA

Zhou, H., Dong, S., Si, Z., Niu, H., Mao, J., Chen, Y., Li, Y., & Wu, W. (2026). Aptamer-based nanoparticle drug delivery system designed for targeting GPC3-positive liver cancer. Journal of Pharmaceutical Analysis, 16(8), 101614. https://doi.org/10.1016/j.jpha.2026.101614

Vancouver

Zhou H, Dong S, Si Z, Niu H, Mao J, Chen Y, et al. Aptamer-based nanoparticle drug delivery system designed for targeting GPC3-positive liver cancer. Journal of Pharmaceutical Analysis. 2026;16(8):101614. doi:10.1016/j.jpha.2026.101614

BibTeX
@article{Zhou2026,
  author = {Zhou, Hongxin and Dong, Shuangshuang and Si, Zhan and Niu, Hao and Mao, Jianwen and Chen, Yiran and Li, Yuhuan and Wu, Weizhong},
  title = {Aptamer-based nanoparticle drug delivery system designed for targeting GPC3-positive liver cancer},
  journal = {Journal of Pharmaceutical Analysis},
  year = {2026},
  volume = {16},
  number = {8},
  pages = {101614},
  doi = {10.1016/j.jpha.2026.101614}
}
Kostenlos starten →